51 / 68
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 3, May/June 2019
AFRICA
179
Antimicrobial Agents Chemother
2010;
55
,1: 203–210. doi: 10.1128/
AAC.01129-10.
25. Francis GS. Modulation of peripheral sympathetic nerve transmission.
J Am Coll Cardiol
1988;
12
: 250–254. PMID: 2837502.
26. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ,
et al
.
Relationship between regional cardiac hyperinnervation and ventricular
arrhythmia.
Circulation
2000;
101
: 1960–1969. PMID: 10779463.
27. Razavi M. Safe and effective pharmacologic management of arrhyth-
mias.
Tex Heart Inst J
2005;
32
(2): 209–211. PMID: 16107117.
28. Chatelain P, Meysmans L, Mattéazzi JR, Beaufort P, Clinet M.
Interaction of the antiarrhythmic agents SR 33589 and amiodarone
with the beta-adrenoceptor and adenylate cyclase in rat heart.
Br J
Pharmacol
1995;
116
: 1939–1956. PMID: 8640331.
29. Galassi G, Georgoulopoulou E, Ariatti A. Amiodarone neurotoxicity:
the other side of the medal.
Centr Eur J Med
2014;
9
(3): 437–442. doi:
10.2478/s11536-013-0306-y.
30. Thijssen V, Ausma J, Borgers M. Structural remodelling during chronic
atrial fibrillation: act of programmed cell survival.
Cardiovasc Res
2001;
52
:14–24. PMID: 11557230.
31. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes
RA,
et al
. Atrial enlargement as a consequence of atrial fibrillation.
A prospective echocardiographic study.
Circulation
1990;
82
: 792–797.
PMID: 2144217.
32. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS,
et
al
. Lifetime risk for development of atrial fibrillation: The Framingham
Heart Study.
Circulation
2004;
110
:1042–1046. doi: 10.1161/01.
CIR.0000140263.20897.42.
33. Shin SH, Park MY, Oh WJ, Hong SJ, Pak HN, Song WH,
et al.
Left
atrial volume is a predictor of atrial fibrillation recurrence after catheter
ablation.
J Am Soc Echocardiogr
2008;
21
: 697–702. doi: 10.1016/j.
echo.2007.10.022.
34. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance
in atrial fibrillation.
J Am Coll Cardiol
2008;
51
: 802–809. doi: 10.1016/j.
jacc.2007.09.064.
35. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation
mechanisms and implications.
Circulation
2008;
1
: 62–73. doi: 10.1161/
CIRCEP.107.754564.
36. Jackevicius CA, Tom A, Essebag V, Eisenberg MJ, Rahme E, Tu JV,
et al
. Population-level incidence and risk factors for pulmonary toxic-
ity associated with amiodarone.
Am J Cardiol
2011;
108
(5): 705–710.
doi:10.1016/j.amjcard.2011.04.024.
37. Zagorianou A, Marougkas M, Drakos S, Diakos N, Konstantopoulos
P, Perrea DN,
et al
. The effect of long-term amiodarone administration
on myocardial fibrosis and evolution of left ventricular remodeling in
a porcine model of ischemic cardiomyopathy.
SpringerPlus
2016;
5
(1):
1568. doi: 10.1186/s40064-016-3249-3.
38. Escudero EM, San Mauro M, Lauglé C. Bilateral atrial function after
chemical cardioversion of atrial fibrillation with amiodarone: an echo-
Doppler study.
J Am Soc Echocardiogr
1998;
11
(4): 365–371. PMID:
9571586.
39. Zapolski T, Wysoki
ń
ski A. Stunning of the left atrium after pharma-
cological cardioversion of atrial fibrillation.
Kardiologia Polska
(
Polish
Heart J
) 2005;
63
(9): 254–262. PMID: 16180181.
40. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-
Hansen A,
et al
. Does elevated C-reactive protein increase atrial fibril-
lation risk? A Mendelian randomization of 47,000 individuals from
the general population.
J Am Coll Cardiol
2010;
56
(10): 789–795. doi:
10.1016/j.jacc.2010.02.066.
41. Narducci ML, Pelargonio G, Dello Russo A, Casella M, Biasucci LM,
La Torre G,
et al
. Role of tissue C-reactive protein in atrial cardio-
myocytes of patients undergoing catheter ablation of atrial fibrilla-
tion: pathogenetic implications.
Europace
2011;
13
(8): 1133–1140. doi:
10.1093/europace/eur068.
42. Yo CH, Lee SH, Chang SS, Lee MCH, Lee CC. Value of high-sensitivity
C-reactive protein assays in predicting atrial fibrillation recurrence: a
systematic review and meta-analysis.
Br Med J Open
2014; 4.2:e004418.
doi: 10.1136/bmjopen-2013-004418.
43. Cabrera-Bueno F, Medina-Palomo C, Ruiz-Salas A, Flores A,
Rodríguez-Losada N, Barrera A,
et al
. Serum levels of interleukin-2
predict the recurrence of atrial fibrillation after pulmonary vein abla-
tion.
Cytokine
2015;
73
(1): 74–78. doi: 10.1016/j.cyto.2015.01.026.
44. Hak Ł, My
ś
liwska J, Wi ckiewicz J, Szyndler K, Siebert J, Rogowski J.
Interleukin-2 as a predictor of early postoperative atrial fibrillation after
cardiopulmonary bypass graft (CABG).
J Interferon Cytokine Res
2009;
29
(6): 327–332. doi: 10.1089/jir.2008.0082.2906.
45. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM,
et al
. Role
of tumor necrosis factor-
α
in the pathogenesis of atrial fibrosis and
development of an arrhythmogenic substrate.
Jpn Circ J
2013;
77
(5):
1171–1179. PMID: 23370453.
46. Deng H, Xue YM, Zhan XZ, Liao HT, Guo HM, Wu SL. Role of
tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation.
Chin Med J
2011;
124
(13): 1976–1982. PMID: 22088456.
47. Çetin S, Mustafa G, Keskin G, Yeter E, Do
ğ
an M, Öztürk MA.
Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities
in patients with rheumatoid arthritis: preliminary results.
Cardiovasc J
Afr
2014;
25
(4): 168–175. doi: 10.5830/CVJA-2014-036.
48. Choi JW, Tae HJ, Oh IH, Lee MK, Shin JH, Kim TH,
et al.
A case of
atrial fibrillation induced by Infliximab in a patient with rheumatoid
arthritis.
J Rheum Dis
2011;
18
(4): 302–305.
https://doi.org/10.4078/jrd.2011.18.4.302.
49. Cheng SM, Lin WH, Lin CS, Ho LJ, Tsai TN, Wu CH,
et al.
Modulation
of both activator protein-1 and nuclear factor-kappa B signal transduc-
tion of human T cells by amiodarone.
Exp Biol Med
(Maywood) 2015;
240
(1): 99–108. doi: 10.1177/1535370214544263.
50. Ito H, Ono K, Nishio R, Sasayama S, Matsumori A. Amiodarone inhib-
its interleukin 6 production and attenuates myocardial injury induced
by viral myocarditis in mice.
Cytokine
2002;
17
: 197–202. doi: 10.1006/
cyto.2001.0996.
51. TachikawaH, KodamaM, Watanabe K, Takahashi T, MaM, Kashimura
T,
et al
. Amiodarone improves cardiac sympathetic nerve function to
hold norepinephrine in the heart, prevents left ventricular
remodeling,
and improves cardiac function in rat dilated cardiomyopathy. Circulation
2005;
111
(7): 894–899. doi: 10.1161/01.CIR.0000155610.49706.D2.
52. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone
inhibits production of tumor necrosis factor-
α
by human mononuclear
cells: a possible mechanism for its effect in heart failure.
Circulation
1997;
96
(5): 1386–1389. PMID: 9315521.
53. Nakajima K, Yamazaki K, Yamada E, Kanaji Y, Kosaka S, Sato K,
et
al.
Amiodarone stimulates interleukin-6 production in cultured human
thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension
culture.
Thyroid
2001;
11
(2): 101–109. doi: 10.1089/105072501300042703.
54. Wiersma M, Meijering RAM, Qi XY, Zhang D, Liu T, Hoogstra-
Berends F,
et al
. Endoplasmic reticulum stress is associated with
autophagy and cardiomyocyte remodeling in experimental and human
atrial fibrillation.
J Am Heart Assoc
2017;
6
.10: e006458. doi: 10.1161/
JAHA.117.006458.
55. Yan J, Zhao W, Thomson JK, Gao X, DeMarco DM, Carrillo E,
et
al
. Stress signaling JNK2 crosstalk with CaMKII underlies enhanced
atrial arrhythmogenesis.
Circ Res
2018;
122
(6): 821–835. doi:10.1161/
CIRCRESAHA.117.312536.